Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Its lead programs are aimed at chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis, with a pipeline built around differentiated product candidates and external licensing collaborations.

−619,0 %

−529,8 %

+85,7 %

8.57

8.57

— Evommune, Inc.
%
Clinical-stage product candidates0% Lead therapeutic programs in human clinical development for chronic inflammatory diseases.
Licensed collaboration revenue100% Upfront and milestone payments from regional or global licensing agreements.
Preclinical pipeline0% Earlier-stage assets and discovery programs intended to broaden the portfolio.

Evommune does not yet commercialize approved products, so its current counterparties are mainly licensing partners...

  • Licensing and collaboration partnersprimary

    Pharma partners that pay upfront fees, milestones, and royalties for regional or global rights to Evommune assets.

  • Future prescribers in dermatology and gastroenterologysecondary

    Specialists who would prescribe approved therapies for CSU, AD, and UC based on efficacy and safety.

  • Patients with chronic inflammatory diseasesecondary

    End users of the therapies, especially patients needing better long-term control of inflammation.

  • Clinical development and research collaboratorssecondary

    CROs, CDMOs, and scientific partners that support trials, manufacturing, and discovery work.

Evommune is headquartered in the United States and operates as a U.S.-based clinical-stage biotech company...

  • •United States headquarters and core operating base
  • •Greater China and selected Asian markets licensed to Maruho
  • •Worldwide rights to EVO301 licensed in from AprilBio
  • •No product-sales geography yet because nothing is commercialized
  • •Future geography will depend on partner-led approvals and launches

Evommune’s strategy is to advance a small number of differentiated inflammation programs through clinical...

01
Advance Phase 2 clinical programsshort-term

Clinical validation is the main value inflection point for a pre-commercial biotech.

02
Expand through partnerships and licensingshort-term

External collaborations can fund development and reduce capital intensity.

03
Broaden the pipeline with preclinical assetsmedium-term

A wider portfolio can improve long-term growth and reduce single-asset dependence.

Evommune is a pre-revenue biotech with no approved products, so its success depends on clinical outcomes, regulatory...

critical

Clinical development failure

Lead assets are still in Phase 2, so efficacy or safety setbacks could eliminate value.

Scope
EVO756 and EVO301
Materiality
high
high

Financing and liquidity pressure

The company has incurred losses since inception and has no product revenue.

Scope
Corporate funding runway
Materiality
high
high

Partner execution risk

Regional and global licensing partners control parts of development and commercialization.

Scope
Maruho and AprilBio agreements
Materiality
medium
high

Commercialization build-out risk

If approved, Evommune lacks sales, marketing, and distribution infrastructure.

Scope
Future product launch
Materiality
medium
medium

Competitive intensity

Large biotech and pharma companies can outspend Evommune in trials and market access.

Scope
Chronic inflammation and immunology markets
Materiality
medium
License revenue recognition
Can create lumpy quarterly results
Accrued research and development expenses
Affects operating expense and net loss
Fair value of preferred stock forward and warrant liabilities
Can add non-cash volatility to reported results
Stock-based compensation
Raises G&A and R&D expense

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

Imunon, Inc.

IMNN · Pharmaceutical Preparations

Evolus, Inc.

EOLS · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

Evolent Health, Inc.

EVH · Services-Management Services

Immunovant, Inc.

IMVT · Biological Products, (No Diagnostic Substances)

: 28.4.2026